AERI:NSD-Aerie Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 11.79

Change

-0.31 (-2.56)%

Market Cap

USD 0.56B

Volume

0.30M

Avg Analyst Target

USD 26.33 (+123.35%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CGC Canopy Growth Corporation

-0.65 (-4.46%)

USD5.57B N/A N/A
TLRY Tilray Inc

-0.35 (-2.91%)

USD5.22B N/A N/A
PCRX Pacira BioSciences Inc

-0.13 (-0.22%)

USD2.58B 15.05 23.27
DVAX Dynavax Technologies Corporati..

+0.23 (+1.17%)

USD2.25B N/A 86.82
CRON Cronos Group Inc

-0.30 (-5.00%)

USD2.19B 37.00 N/A
IRWD Ironwood Pharmaceuticals Inc

+0.46 (+3.54%)

USD2.12B 4.15 9.52
ORGO Organogenesis Holdings Inc

-0.19 (-1.22%)

USD2.07B 28.71 23.24

ETFs Containing AERI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.73% 52% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.73% 52% F 25% F
Trailing 12 Months  
Capital Gain 5.17% 52% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.17% 52% F 26% F
Trailing 5 Years  
Capital Gain -69.82% 35% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.82% 35% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain -14.52% 22% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.52% 22% F 6% F
Risk Return Profile  
Volatility (Standard Deviation) 39.79% 63% D 46% F
Risk Adjusted Return -36.49% 22% F 7% F
Market Capitalization 0.56B 71% C- 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 34.26 7% F 3% F
Price / Cash Flow Ratio -8.64 66% D 71% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -663.12% 5% F 11% F
Return on Invested Capital -54.56% 31% F 15% F
Return on Assets -22.77% 34% F 16% F
Debt to Equity Ratio 877.72% 7% F 2% F
Technical Ratios  
Short Ratio 13.71 11% F 6% F
Short Percent 11.97% 27% F 13% F
Beta 0.72 85% B 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector